AMG 102

Generic Name: AMG 102
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20040167Advanced solid tumors1A Phase 1, First in Human, Open Label, Sequential Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 102 in Patients with Advanced Solid Tumors
20050177Advanced Solid Tumors1bAn Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102 with AMG 706 and AMG 102 with Bevacizumab in Adult Subjects With Advanced Solid Tumors
20050253Advanced Malignant Glioma2A Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Malignant Glioma
20060100Advanced Renal Cell Carcinoma2A Global, Multicenter, Open-label, Single Agent, Two-stage, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Renal Cell CarcinomaA Global, Multicenter, Open-label, Single Agent, Two-stage, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Renal Cell Carcinoma
20060317Previously untreated subjects with unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma.1b/2A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction  Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin, Cisplatin, and Capecitabine (ECX) plus AMG 102
20070611Subjects with castrate-resistant prostate cancer who have received prior taxane-based chemotherapy.1b/2A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer
20070622First-line treatment of subjects with locally advanced or metastatic MET-positive gastric, lower esophageal, or gastroesophageal junction (GEJ) adenocarcinoma.3A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
20110251Part 1: Unresectable locally advanced or metastatic carcinoma Part 2: Unresectable locally advanced or metastatic gastric or esophagogastric junction (GEJ) adenocarcinoma1/1bA Multicenter, Phase 1/1b, Open Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Rilotumumab (AMG 102) in Japanese Subjects
20120142First-line treatment of subjects with locally advanced or metastatic mesenchymal epithelial transition factor (MET)-positive gastric, lower esophageal or gastroesophageal junction (GEJ) adenocarcinoma3 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma